Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 12/20 | 0.41 |
| ▸ | CA1 | P00915 | 12/20 | 0.41 |
| ▸ | CA2 | P00918 | 11/20 | 0.41 |
| ▸ | CA5A | P35218 | 9/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 9/20 | 0.41 |
| ▸ | CA4 | P22748 | 8/20 | 0.41 |
| ▸ | CA7 | P43166 | 8/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8946081 | 1.00 | TSHR (0.47) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL9007988 | 0.81 | TSHR (0.55) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL9007984 | 0.81 | TSHR (0.55) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL6285257 | 0.80 | CYP2D6 (0.48) | TSHRCA12CA1CA2CA5A | |
| SCHEMBL22556156 | 0.80 | CYP2D6 (0.48) | TSHRCA12CA1CA2CA5A | |
| SCHEMBL22556152 | 0.80 | CYP2D6 (0.48) | TSHRCA12CA1CA2CA5A | |
| SCHEMBL28635606 | 0.79 | CYP2D6 (0.47) | TSHRCA12CA1CA2CA5A | |
| SCHEMBL6207548 | 0.79 | TSHR (0.50) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL13945304 | 0.79 | CYP2D6 (0.44) | TSHRCA12CA1CA2CA5A | |
| SCHEMBL20211464 | 0.78 | CYP3A4 (0.47) | MEN1USP2LMNACYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605136-B2 | Epothilone - saccharide complex; antiproliferative agents; antitumor agents; antiinflammatory agents; central nervous system disorders; multiple sclerosis; Alzheimer's disease; rheumatic disorders; antiarthritic agents | BAYER SCHERING PHARMA AG (DE) | 2009-10-20 | — | — | US | claimed |
| US-20060276413-A1 | New effector conjugates, methods for their preparation and their pharmaceutical use | BOSSLET KLAUS | 2006-12-07 | — | — | US | claimed |
| EP-1581218-A1 | EPOTHILONE ANALOGS FOR SITE SPECIFIC DELIVERY IN THE TREATMENT OF PROLIFERATIVE DISEASES | Schering AG (DE) | 2005-10-05 | — | — | EP | claimed |
| US-20040167083-A1 | Effector conjugates, methods for their preparation and their pharmaceutical use | SCHERING AG (DE) | 2004-08-26 | — | — | US | claimed |
| WO-2004050089-A1 | EPOTHILONE ANALOGS FOR SITE SPECIFIC DELIVERY IN THE TREATMENT OF PROLIFERATIVE DISEASES | SCHERING AG (DE) | 2004-06-17 | — | — | WO | claimed |
| EP-0511917-B1 | Glycosylated prodrugs, process for their preparation and uses thereof | HOECHST SA LAB (FR) | 1996-10-23 | — | — | EP | claimed |
| US-5561119-A | ANTITUMOR AGENTS | LABORATOIRES HOECHST (FR) | 1996-10-01 | — | — | US | claimed |
| US-7605136-B2 | Epothilone - saccharide complex; antiproliferative agents; antitumor agents; antiinflammatory agents; central nervous system disorders; multiple sclerosis; Alzheimer's disease; rheumatic disorders; antiarthritic agents | BAYER SCHERING PHARMA AG (DE) | 2009-10-20 | — | — | US | disclosed |
| US-20090076098-A1 | METHODS, KITS, AND COMPOUNDS FOR DETERMINING RESPONSIVENESS TO TREATMENT OF A PATHOLOGICAL DISORDER BY EPOTHILONES | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-2009114-A1 | Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20060276413-A1 | New effector conjugates, methods for their preparation and their pharmaceutical use | BOSSLET KLAUS | 2006-12-07 | — | — | US | disclosed |
| US-20040167083-A1 | Effector conjugates, methods for their preparation and their pharmaceutical use | SCHERING AG (DE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076098-A1 | METHODS, KITS, AND COMPOUNDS FOR DETERMINING RESPONSIVENESS TO TREATMENT OF A PATHOLOGICAL DISORDER BY EPOTHILONES | LANCL1, DHPS, TXNRD2 | TSHR 1737/4885PTPN1 3114/4885CA12 1632/4885 |
| US-20060276413-A1 | New effector conjugates, methods for their preparation and their pharmaceutical use | EPOR, FLT4, SELE | TSHR 1990/4885PTPN1 1844/4885CA12 1062/4885 |
| US-20040167083-A1 | Effector conjugates, methods for their preparation and their pharmaceutical use | EPOR, SELE, FLT1 | TSHR 1582/4885PTPN1 1953/4885CA12 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.